{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:27:11Z","timestamp":1785342431137,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T00:00:00Z","timestamp":1286409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00280-010-1474-y","type":"journal-article","created":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T11:38:56Z","timestamp":1286365136000},"page":"239-245","source":"Crossref","is-referenced-by-count":35,"title":["High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid"],"prefix":"10.1007","volume":"68","author":[{"given":"Werner J.","family":"Heinz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegret","family":"Helle-Beyersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Lenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,7]]},"reference":[{"key":"1474_CR1","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109","journal-title":"Cancer Res"},{"key":"1474_CR2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","volume":"69","author":"GM Keating","year":"2009","unstructured":"Keating GM, Santoro A (2009) Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69:223\u2013240","journal-title":"Drugs"},{"key":"1474_CR3","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312\u20133318","journal-title":"J Clin Oncol"},{"key":"1474_CR4","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271\u20137278","journal-title":"Clin Cancer Res"},{"key":"1474_CR5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"1474_CR6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.6004\/jnccn.2009.0027","volume":"7","author":"AB Benson 3rd","year":"2009","unstructured":"Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D\u2019Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350\u2013391","journal-title":"J Natl Compr Canc Netw"},{"key":"1474_CR7","doi-asserted-by":"crossref","unstructured":"Villanueva A, Minguez B, Forner A, Reig M, Llovet JM Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61: 317\u2013328","DOI":"10.1146\/annurev.med.080608.100623"},{"key":"1474_CR8","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907\u20131917","journal-title":"Lancet"},{"key":"1474_CR9","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res 66:11851\u201311858","journal-title":"Cancer Res"},{"key":"1474_CR10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejca.2005.11.014","volume":"42","author":"D Strumberg","year":"2006","unstructured":"Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B (2006) Pooled safety analysis of BAY 43\u20139006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 42:548\u2013556","journal-title":"Eur J Cancer"},{"key":"1474_CR11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0021-9673(01)00669-0","volume":"917","author":"J Coleman","year":"2001","unstructured":"Coleman J, Wrzosek T, Roman R, Peterson J, McAllister P (2001) Setting system suitability criteria for detectability in high-performance liquid chromatography methods using signal-to-noise ratio statistical tolerance intervals. J Chromatogr A 917:23\u201327","journal-title":"J Chromatogr A"},{"key":"1474_CR12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0731-7085(97)00198-2","volume":"17","author":"C Hartmann","year":"1998","unstructured":"Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD (1998) Validation of bioanalytical chromatographic methods. J Pharm Biomed Anal 17:193\u2013218","journal-title":"J Pharm Biomed Anal"},{"key":"1474_CR13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jpba.2007.10.027","volume":"46","author":"L Jain","year":"2008","unstructured":"Jain L, Gardner ER, Venitz J, Dahut W, Figg WD (2008) Development of a rapid and sensitive LC-MS\/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal 46:362\u2013367","journal-title":"J Pharm Biomed Anal"},{"key":"1474_CR14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jchromb.2008.12.026","volume":"877","author":"RW Sparidans","year":"2009","unstructured":"Sparidans RW, Vlaming ML, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH (2009) Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. J Chromatogr B Analyt Technol Biomed Life Sci 877:269\u2013276","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1474_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2006.06.005","volume":"846","author":"M Zhao","year":"2007","unstructured":"Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BD, Messersmith WA, Hidalgo M, Baker SD (2007) A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography\/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 846:1\u20137","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1474_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jchromb.2004.06.003","volume":"809","author":"S Afify","year":"2004","unstructured":"Afify S, Rapp UR, Hogger P (2004) Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. J Chromatogr B Analyt Technol Biomed Life Sci 809:99\u2013103","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1474_CR17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jpba.2009.02.008","volume":"49","author":"B Blanchet","year":"2009","unstructured":"Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F, Tod M (2009) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 49:1109\u20131114","journal-title":"J Pharm Biomed Anal"},{"key":"1474_CR18","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","volume":"11","author":"JW Clark","year":"2005","unstructured":"Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43\u20139006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472\u20135480","journal-title":"Clin Cancer Res"},{"key":"1474_CR19","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","volume":"92","author":"A Awada","year":"2005","unstructured":"Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21\u00a0days on\/7\u00a0days off in patients with advanced, refractory solid tumours. Br J Cancer 92:1855\u20131861","journal-title":"Br J Cancer"},{"key":"1474_CR20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","volume":"99","author":"J Furuse","year":"2008","unstructured":"Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159\u2013165","journal-title":"Cancer Sci"},{"key":"1474_CR21","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293\u20134300","journal-title":"J Clin Oncol"},{"key":"1474_CR22","doi-asserted-by":"crossref","unstructured":"Chen K-F, Yu H-C, Liu T-H, Lee S-S, Chen P-J, Cheng A-L Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 52: 88\u201395","DOI":"10.1016\/j.jhep.2009.10.011"},{"key":"1474_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","volume":"43","author":"K Mross","year":"2007","unstructured":"Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, Brendel E, Christensen O, Unger C (2007) Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43:55\u201363","journal-title":"Eur J Cancer"},{"key":"1474_CR24","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/S0168-8278(09)60538-9","volume":"50","author":"AC Piguet","year":"2009","unstructured":"Piguet AC, Radojevic V, Afthinos M, Hora C, Ledermann M, Saar B, Dufour JF (2009) 536 The combination everolimus (RAD001) plus sorafenib is superior to sorafenib monotherapy in the treatment of hepatocellular carcinoma. J Hepatol 50:S199\u2013S200","journal-title":"J Hepatol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1474-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1474-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1474-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T02:43:43Z","timestamp":1711853023000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1474-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1474-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,7]]}}}